Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis - PubMed (original) (raw)
Meta-Analysis
Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis
L A García Rodríguez. Semin Arthritis Rheum. 1997 Jun.
Abstract
Nonsteroidal antiinflammatory drugs (NSAIDs) are associated with a high prevalence of gastrointestinal toxicity. Comparisons of the risks associated with individual NSAIDs are needed, but most clinical studies in this area are not ideally suited for use in meta-analyses. These difficulties can be overcome by using strict criteria for the inclusion of studies, and by reanalyzing previous data, updated by authors where possible. In doing so, this meta-analysis compared the relative risk of serious toxicity associated with 14 NSAIDs from 12 studies with the risks of ibuprofen. These results were supported by a novel "summary ranking" analysis, which was weighted to limit the influence of smaller studies. Wide variations in relative risk among NSAIDs were observed with piroxicam and azapropazone being the most toxic. Ibuprofen was associated with the least risk, probably because of its widespread use as a low-dose analgesic. Five studies provided comparative data on NSAIDs at "high" and "low" doses (as defined in the original reports), showing that the risk of toxicity was dose related. Furthermore, at full antiinflammatory doses, the risk associated with ibuprofen was similar to that of naproxen and diclofenac. These analyses show that NSAIDs vary more in toxicity than in efficacy. First-line therapy should be started with the lowest effective dose of a less toxic NSAID, moving to higher doses or a more toxic NSAID only if the clinical situation demands it. Newer NSAIDs, such as selective cyclooxygenase-2 inhibitors, may provide safer antiinflammatory therapy.
Similar articles
- Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Silverstein FE, et al. JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247. JAMA. 2000. PMID: 10979111 Clinical Trial. - Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs.
García Rodríguez LA. García Rodríguez LA. Am J Med. 1998 Mar 30;104(3A):30S-34S; discussion 41S-42S. doi: 10.1016/s0002-9343(97)00208-8. Am J Med. 1998. PMID: 9572318 - Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
[No authors listed] [No authors listed] Prescrire Int. 2007 Dec;16(92):223-7. Prescrire Int. 2007. PMID: 18084859 - Non-steroidal anti-inflammatory drug gastropathy: causes and treatment.
Hawkey CJ. Hawkey CJ. Scand J Gastroenterol Suppl. 1996;220:124-7. doi: 10.3109/00365529609094763. Scand J Gastroenterol Suppl. 1996. PMID: 8898449 Review. - NSAIDs, gastrointestinal toxicity and inflammatory bowel disease.
Hijos-Mallada G, Sostres C, Gomollón F. Hijos-Mallada G, et al. Gastroenterol Hepatol. 2022 Mar;45(3):215-222. doi: 10.1016/j.gastrohep.2021.06.003. Epub 2021 Jun 19. Gastroenterol Hepatol. 2022. PMID: 34157367 Review. English, Spanish.
Cited by
- A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients.
Sugisaki N, Iwakiri R, Tsuruoka N, Sakata Y, Shimoda R, Fujimoto S, Eguchi Y, Fujimoto K. Sugisaki N, et al. J Gastroenterol. 2018 Dec;53(12):1253-1260. doi: 10.1007/s00535-018-1483-x. Epub 2018 Jun 12. J Gastroenterol. 2018. PMID: 29948304 - Management for non-variceal upper gastrointestinal bleeding in elderly patients: the experience of a tertiary university hospital.
Kawaguchi K, Kurumi H, Takeda Y, Yashima K, Isomoto H. Kawaguchi K, et al. Ann Transl Med. 2017 Apr;5(8):181. doi: 10.21037/atm.2017.03.103. Ann Transl Med. 2017. PMID: 28616396 Free PMC article. - New developments in the pharmacotherapy of neuropathic chronic pelvic pain.
Carey ET, As-Sanie S. Carey ET, et al. Future Sci OA. 2016 Oct 5;2(4):FSO148. doi: 10.4155/fsoa-2016-0048. eCollection 2016 Dec. Future Sci OA. 2016. PMID: 28116131 Free PMC article. Review. - Pharmacological Management of Chronic Pelvic Pain in Women.
Carey ET, Till SR, As-Sanie S. Carey ET, et al. Drugs. 2017 Mar;77(3):285-301. doi: 10.1007/s40265-016-0687-8. Drugs. 2017. PMID: 28074359 Review. - Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance.
Brooks J, Warburton R, Beales IL. Brooks J, et al. Ther Adv Chronic Dis. 2013 Sep;4(5):206-22. doi: 10.1177/2040622313492188. Ther Adv Chronic Dis. 2013. PMID: 23997925 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials